Systemic Sclerosis: Clinical Trials

12 trials for Systemic Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed. 12 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 12
Phase 22Completed 2

Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effectiveness of Cannabinoids on Appetite in Scleroderma
CBD oil, Placebo - Systemic Sclerosis, Malnutrition
Phase 3CompletedKhon Kaen University302022-11-092025-02-20
Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis
CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms
Phase 2 / Phase 3CompletedIRCCS San Raffaele162020-05-012024-01-30
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
Mycophenolate mofetil, Placebo - Systemic Sclerosis, Scleroderma
Phase 3CompletedPost Graduate Institute of Medical Education and Research, Chandigarh412016-10-012018-06-06
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
Placebo, Tocilizumab - Systemic Sclerosis
Phase 3CompletedHoffmann-La Roche2122015-11-202020-03-09
Gastroesophageal Reflux Treatment in Scleroderma
Alginic acid, placebo (for domperidone), Domperidone - Gastroesophageal Reflux Disease, Systemic Sclerosis
Phase 3CompletedKhon Kaen University802013-06-012017-03-27
Rituximab in Systemic Sclerosis
Rituximab, Placebo (NaCl) - Systemic Sclerosis
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris222013-04-092025-11-20
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Cyclophosphamide, Placebo - Systemic Sclerosis, Scleroderma
Phase 3CompletedAssistance Publique - Hôpitaux de Paris402013-01-142025-09-12
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
macitentan 3mg, macitentan 10mg, placebo - Systemic Sclerosis, Ulcers
Phase 3CompletedActelion2892011-12-012015-01-06
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
Rosuvastatin - Systemic Sclerosis
Phase 3CompletedUniversity of Alexandria402008-09-012009-09-25
Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
Bosentan 62.5 mg, Bosentan 125 mg, Placebo - Digital Ulcers, Systemic Sclerosis
Phase 3CompletedActelion1882003-10-012025-02-03
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Relaxin - Systemic Sclerosis
Phase 3CompletedUniversity of Medicine and Dentistry of New Jersey2311998-12-012008-06-25
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
iloprost - Systemic Sclerosis, Raynaud Disease
Phase 3CompletedNational Center for Research Resources (NCRR)2001995-12-012005-06-24

Narrower conditions

Scleroderma, Systemic (12)  ·  Scleroderma, Diffuse (7)  ·  Arthritis (2)  ·  Lung Diseases, Interstitial (2)  ·  Pulmonary Fibrosis (2)  ·  digital ulcers (2)  ·  Anorexia (1)  ·  Connective Tissue Diseases (1)  ·  Gastroesophageal Reflux (1)  ·  Hypertension, Pulmonary (1)  ·  Malnutrition (1)  ·  Rare Diseases (1)  ·  Raynaud Disease (1)  ·  Respiratory Tract Diseases (1)  ·  Sexual Dysfunctions, Psychological (1)

Broader conditions

Skin Diseases (12)  ·  Skin and Connective Tissue Diseases (12)  ·  Connective Tissue Diseases (11)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Lung Diseases (4)  ·  Pathologic Processes (4)  ·  Respiratory Tract Diseases (4)  ·  Cardiovascular Diseases (2)  ·  Fibrosis (2)  ·  Joint Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Vascular Diseases (2)  ·  Deglutition Disorders (1)  ·  Digestive System Diseases (1)  ·  Disease Attributes (1)

Interventions

Alginic Acid (1)  ·  Bosentan (1)  ·  Cyclophosphamide (1)  ·  Domperidone (1)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)  ·  Iloprost (1)  ·  Mycophenolic Acid (1)  ·  Relaxin (1)  ·  Rituximab (1)  ·  Rosuvastatin Calcium (1)  ·  macitentan (1)  ·  tocilizumab (1)

Sponsors

Actelion (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Khon Kaen University (2)  ·  Hoffmann-La Roche (1)  ·  IRCCS San Raffaele (1)  ·  National Center for Research Resources (NCRR) (1)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (1)  ·  University of Alexandria (1)  ·  University of Medicine and Dentistry of New Jersey (1)

Countries

France (3)  ·  Italy (3)  ·  Bulgaria (2)  ·  Canada (2)  ·  Denmark (2)  ·  Germany (2)  ·  Hungary (2)  ·  India (2)  ·  Poland (2)  ·  Thailand (2)  ·  United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belarus (1)  ·  Belgium (1)

Top investigators

Anna Abou-Raya (1)  ·  Chingching Foocharoen, M.D. (1)  ·  Chingching Foocharoen, MD (1)  ·  James Seibold, MD (1)  ·  Luc Mouthon, MD, PhD (1)  ·  Thomas A. Medsger, Jr. (1)  ·  Yannick Allanore, MD, PhD (1)

Results publications

PMID 20805294, PMID 27163986, PMID 27179107, PMID 31813058, PMID 32866440, PMID 33294861, PMID 33538094, PMID 33765691, PMID 34851799, PMID 37228011, PMID 41137182

NIH funding

2015 (1)